The degree to which an effect on a histopathologic surrogate endpoint will ultimately yield benefits 'remains mired in uncertainty.' • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
